Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

180.75GBp
11:51am EDT
Change (% chg)

-13.90 (-7.14%)
Prev Close
194.65
Open
191.05
Day's High
191.60
Day's Low
179.75
Volume
4,686,800
Avg. Vol
3,664,119
52-wk High
504.60
52-wk Low
169.30

Select another date:

Wed, Sep 26 2018

Indivior slashes revenue outlook for Sublocade, shares tank

Indivior Plc cut its expectations for revenue from injectable opioid addiction drug Sublocade on Wednesday and said it had "substantially underestimated" the delay in getting the drug to patients although it remained confident of its potential.

UPDATE 2-Indivior slashes revenue outlook for Sublocade, shares tank

* Shares plunge over 16 pct (Adds details, background, CEO comment)

Indivior sharply lowers revenue outlook for opioid addiction drug Sublocade

Sept 26 Indivior Plc revised its full-year earnings guidance as it sharply lowered its revenue expectation for opioid addiction drug Sublocade on Wednesday.

Teva to hold Indivior generic drug launch pending U.S. ruling

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

UPDATE 1-Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

Aug 8 The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Indivior: U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

UPDATE 1-Indivior: U.S. court rules against generic rival's appeal

July 31 Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Select another date: